Skip to main content
. 2014 May 16;9(5):e97928. doi: 10.1371/journal.pone.0097928

Table 3. The association of metabolic syndrome with albuminuria and retinopathy.

Isolated albuminuria Isolated retinopathy Albuminuria combined with retinopathy
Adjusted odds ratio (95%CI) Adjusted odds ratio (95%CI) Adjusted odds ratio (95%CI)
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
MetS (IDF) 1.15(0.95–1.39) 1.60(1.02–2.5)* 1.79(0.96–3.34)
MetS (ATP III) 1.16(0.96–1.40) 1.53(0.98–2.38) 1.85(0.97–3.53)
Waist circumference ≥90 cm (male), ≥80 cm (female) 1.24(1.04–1.50)* 1.13(0.93–1.38) 1.59(1.02–2.48)* 1.52(0.95–2.41) 1.54(0.82–2.86) 1.36(0.70–2.66)
Triglyceride ≥1.7 mmol/L 1.13(0.93–1.36) 1.03(0.84–1.26) 0.74(0.47–1.19) 0.57(0.35–0.94)* 0.81(0.42–1.57) 0.58(0.29–1.17)
HDL-cholesterol <1.03 mmol/L (male), <1.29 mmol/L (female) 1.13(0.94–1.36) 1.10(0.90–1.34) 1.20(0.77–1.87) 1.21(0.76–1.93) 1.29(0.69–2.41) 1.24(0.64–2.39)
Blood pressure≥130/85 mmHg 1.49(1.22–1.82)** 1.51(1.22–1.86)* 1.79(1.07–3.01)* 1.68(0.99–2.86) 1.75(0.87–3.52) 1.79(0.83–3.84)
FPG≥5.6 mmol/L 0.90(0.75–1.08) 0.84(0.69–1.02) 1.71(1.06–2.74)* 1.60(0.99–2.58) 3.12(1.48–6.59)** 3.04(1.37–6.74)**
MetS (CDS) 1.24(1.03–1.51)* 1.80(1.16–2.79)** 2.02(1.09–3.77)*
BMI≥25.0 kg/m2 1.11(0.93–1.33) 1.02(0.84–1.24) 1.12(0.73–1.73) 0.93(0.59–1.46) 1.68(0.92–3.06) 1.51(0.79–2.89)
Blood pressure≥140/90 mmHg 1.57(1.30–1.90)** 1.59(1.30–1.95)** 2.31(1.42–3.77)** 2.25(1.36–3.73)** 1.61(0.85–3.05) 1.45(0.73–2.89)
Triglyceride ≥1.7 mmol/l, or HDL-cholesterol<0.9 mmol/L(male), <1.0 mmol/L(female) 1.18(0.98–1.42) 1.12(0.92–1.36) 0.90(0.58–1.41) 0.70(0.44–1.11) 1.00(0.53–1.89) 0.71(0.36–1.37)
IGR or diabetes 0.94(0.78–1.13) 0.85(0.69–1.03) 2.33(1.42–3.84)** 2.22(1.33–3.7)** 2.88(1.42–5.83)** 3.17(1.45–6.93)**

Model 1, adjusted for age and sex. Model 2, adjusted for age, sex, and all other metabolic components. CI, confidence interval. IGR, impaired glucose regulation.

*P<0.05,

**P<0.01.BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose;HDL, high density lipoprotein; IGR, impaired glucose regulation; MetS, metabolic syndrome.